CTXR Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Stats
Today's Volume	2.77M
Average Volume	881 503
Market Cap	105.77M
EPS	$-0.0700 ( 2024-02-09 )
Next earnings date	( $-0.0600 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.56
ATR14	$0.00200 (0.30%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-03	Mazur Leonard L	Buy	1 165 048	Warrant to Purchase Common Stock
2024-04-03	Mazur Leonard L	Sell	1 165 048	Warrant to Purchase Common Stock
2024-04-03	Holubiak Myron Z	Buy	129 450	Warrant to Purchase Common Stock
2024-04-03	Holubiak Myron Z	Sell	129 450	Warrant to Purchase Common Stock
2024-03-14	Smith Robert Joseph	Buy	75 000	Stock Option (Right to Purchase Common Stock)

INSIDER POWER
43.34
Last 96 transactions
Buy: 27 334 255 \| Sell: 1 367 765

Volume Correlation

Long: 0.26 (neutral)

Short: -0.17 (neutral)

Signal:(48.664) Neutral

Citius Pharmaceuticals Correlation

10 Most Positive Correlations
FICS	0.886
HEAR	0.877
RNEM	0.868
VIGI	0.866
NTRSO	0.865
RMRM	0.861
PID	0.86
TCON	0.856
TZOO	0.856
GAINL	0.854

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Citius Pharmaceuticals Correlation - Currency/Commodity

0.00
( neutral )

0.01
( neutral )

Citius Pharmaceuticals Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-194 316 (0.00 %)
EPS:	$-0.220

FY	2023
Revenue:	$0
Gross Profit:	$-194 316 (0.00 %)
EPS:	$-0.220

FY	2022
Revenue:	$0
Gross Profit:	$-179 677 (0.00 %)
EPS:	$-0.230

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.230

Financial Reports:

No articles found.

Citius Pharmaceuticals

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.